Bankhaus Lampe KG announced EVOTEC (ETR:EVT), bumping up its stock price target to 6.50EUR today
- Updated: November 25, 2016
In a report issued 11/26/2016 Bankhaus Lampe KG upped the price target of EVOTEC (ETR:EVT) to 6.50EUR stating a potential upside of 0.07%.
On Friday November 25, 2016, Bankhaus Lampe KG released a statement for EVOTEC (ETR:EVT) bumped up the target price from 0.00EUR to 6.50EUR that suggested an upside of 0.08%.
Boasting a price of 6.06EUR, EVOTEC (ETR:EVT) traded 0.50% higher on the day. With the last stock price close down -0.01% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.03% over the date range. EVOTEC has recorded a 50-day average of 19.68EUR and a two hundred day average of 20.25EUR. Volume of trade was down over the average, with 72,804 shares of EVT changing hands under the typical 138,516
With a total market value of 0 EUR, EVOTEC has with a one year low of 16.37EUR and a one year high of 21.25EUR .
Brief Synopsis About EVOTEC (ETR:EVT)
Evotec AG (Evotec) is a drug discovery and development company. The Company is engaged in providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors. The Company has two segments: EVT Execute and EVT Innovate. EVT Execute segment offers stand-alone or integrated drug discovery solutions for collaborator's targets and programs. EVT Innovate focuses on developing its internal assets, including early-stage discovery programs, as well as drug candidates. The Company focuses on therapeutic areas, including central nervous system (CNS)/neurology, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. Its clinical products include EVT302, EVT201, EVT100 and EVT401. Its pre-clinical products include EVT770, EVT801, EVT701 and EVT601. EVT302 is an inhibitor of monoamine oxidase type B (MAO-B), an enzyme that breaks down the chemical messenger dopamine in the brain and contributes to the production of free radicals.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.